Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
From a drug standpoint, there are two major areas that I find very
interesting right now. One of the antiangiogenic agents — we,
at Indiana University have been looking at antiangiogenic agents
in the laboratory and now in the clinic for several years. The other
area that I think dove-tails very nicely with the antiangiogenic
agents are the tyrosine kinase inhibitors. We are going to see an
explosion of TK inhibitors entering the clinic over the next few
years. I think these are going to have a fairly profound influence
on how we practice medicine. There are going to be several of them
that are going to be coming into the clinic in the fairly near future.
I think, based on the pre-clinic models, you can kind of break them
down into sort of two broad groups. One are the sort of highly selected
ones, ones that will just knock out a single tyrosine kinase. The
other are ones that are somewhat more promiscuous, that may for
instance knock out both the epidermal growth factor receptor and
one of the VEGF receptors. And this is kind of a fascinating thought,
that you’ll be able, using the same oral medicine, be able
to knock out both angiogenesis and growth at the same time. But,
a drug very much like that will be entering the clinic in the fairly
near future.
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody
therapy [Review]. Pegram, M. and Slamon, D Seminars in Oncology.
27(5 Suppl 9):13-19, 2000 Oct.
In
process Current and planned clinical trials with trastuzumab (Herceptin)
[Review]. Baselga, J. Seminars in Oncology. 27(5 Suppl 9):27-32, 2000
Oct. In process
Clinical
trials of single-agent trastuzumab (Herceptin) [Review]. Seminars in Oncology. 27(5 Suppl 9):20-26, 2000 Oct. In proces
